Preoperative hemoglobin-to-red cell distribution width ratio as a prognostic factor in pulmonary large cell neuroendocrine carcinoma: a retrospective cohort study.

Pulmonary large cell neuroendocrine carcinoma (PLCNEC) hemoglobin (Hgb) hemoglobin-to-red blood cell distribution ratio (HRR) overall survival (OS) red blood cell distribution ratio

Journal

Annals of translational medicine

ISSN: 2305-5839

Titre abrégé: Ann Transl Med

Pays: China

ID NLM: 101617978

Informations de publication

Date de publication:
Jan 2022

Historique:

received: 09 11 2021

accepted: 05 01 2022

entrez: 14 3 2022

pubmed: 15 3 2022

medline: 15 3 2022

Statut: ppublish

Résumé

The hemoglobin (Hgb)/red cell distribution width (RDW) ratio (HRR) is a simple prognostic marker for small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), but no data are available for pulmonary large cell neuroendocrine carcinoma (PLCNEC). This study aimed to assess the potential prognostic role of preoperative HRR in PLCNEC. This single-center retrospective study included patients with PLCNEC who underwent surgery at Shanghai Pulmonary Hospital from January 2012 to August 2016. The follow-up was censored in August 2020. The participants were grouped as low/high HRR according to their optimal value calculated using a receiver operating characteristic (ROC) curve. Univariable and multivariable Cox analysis were performed to identify the risk factors for overall survival (OS). A total of 80 patients with PLCNEC were included. The optimal cutoff values were 0.969 for HRR. Compared with the high HRR group, the low HRR group had a lower mean Hgb (12.1 Low HRR is associated with poor OS in patients with PLCNEC and can be used as an inexpensive prognostic factor in patients undergoing PLCNEC resection.

Sections du résumé

Background UNASSIGNED

Methods UNASSIGNED

This single-center retrospective study included patients with PLCNEC who underwent surgery at Shanghai Pulmonary Hospital from January 2012 to August 2016. The follow-up was censored in August 2020. The participants were grouped as low/high HRR according to their optimal value calculated using a receiver operating characteristic (ROC) curve. Univariable and multivariable Cox analysis were performed to identify the risk factors for overall survival (OS).

Results UNASSIGNED

A total of 80 patients with PLCNEC were included. The optimal cutoff values were 0.969 for HRR. Compared with the high HRR group, the low HRR group had a lower mean Hgb (12.1

Conclusions UNASSIGNED

Low HRR is associated with poor OS in patients with PLCNEC and can be used as an inexpensive prognostic factor in patients undergoing PLCNEC resection.

Identifiants

DOI: 10.21037/atm-21-6348 PMID: 35282116 PMC: PMC8848384

pubmed: 35282116

doi: 10.21037/atm-21-6348

pii: atm-10-02-42

pmc: PMC8848384

doi:

Types de publication

Journal Article

Langues

eng

Pagination

Informations de copyright

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-21-6348/coif). The authors have no conflicts of interest to declare.

Références

Ir J Med Sci. 2020 Feb;189(1):91-102

pubmed: 31832860

Oncotarget. 2016 Jul 5;7(27):42650-42660

pubmed: 27223088

Nutr Cancer. 2017 Nov-Dec;69(8):1151-1176

pubmed: 29083236

Eur J Clin Nutr. 2020 Nov;74(11):1519-1535

pubmed: 32366995

Semin Oncol. 2019 Feb;46(1):48-56

pubmed: 30655021

Eur J Surg Oncol. 2017 Jan;43(1):1-14

pubmed: 27406973

J Thorac Dis. 2016 Dec;8(12):3658-3666

pubmed: 28149561

Ann Thorac Surg. 2021 Aug;112(2):405-414

pubmed: 33130114

Biomed Pharmacother. 2016 May;80:127-135

pubmed: 27133049

Eur Arch Otorhinolaryngol. 2018 Nov;275(11):2869-2878

pubmed: 30251123

Arch Bronconeumol. 2014 Sep;50(9):392-6

pubmed: 24685201

PLoS One. 2013 Nov 11;8(11):e80240

pubmed: 24244659

Ann Transl Med. 2018 Apr;6(8):146

pubmed: 29862235

Trends Cancer. 2016 Dec;2(12):758-770

pubmed: 28741521

Eur J Cardiothorac Surg. 2014 Jan;45(1):108-13

pubmed: 23711463

Haematologica. 2015 Oct;100(10):e387-9

pubmed: 26113420

PLoS One. 2020 Aug 24;15(8):e0237947

pubmed: 32833961

Lung Cancer. 2007 Mar;55(3):357-63

pubmed: 17141357

Transl Lung Cancer Res. 2017 Oct;6(5):530-539

pubmed: 29114469

Rep Pract Oncol Radiother. 2020 Sep-Oct;25(5):768-774

pubmed: 32802001

Int J Clin Exp Med. 2015 Mar 15;8(3):4228-35

pubmed: 26064334

Obstet Gynecol Sci. 2014 Jan;57(1):28-36

pubmed: 24596815

J Thorac Cardiovasc Surg. 2005 Jul;130(1):166-72

pubmed: 15999058

Am J Pathol. 2005 Sep;167(3):627-35

pubmed: 16127144

J Clin Med Res. 2013 Apr;5(2):121-6

pubmed: 23518817

Biomark Med. 2020 Jun;14(9):727-738

pubmed: 32648774

Cancer Treat Rev. 2009 Dec;35(8):738-43

pubmed: 19733008

Clin Transl Radiat Oncol. 2019 Jan 24;16:28-33

pubmed: 30923751

PLoS One. 2015 Aug 27;10(8):e0136033

pubmed: 26313452

Semin Thorac Cardiovasc Surg. 2006 Fall;18(3):206-10

pubmed: 17185180

Cytokine. 2012 May;58(2):158-61

pubmed: 22326661

Thorac Cancer. 2019 Apr;10(4):751-760

pubmed: 30734490

Future Oncol. 2021 Oct;17(29):3853-3864

pubmed: 34382414

Intern Med. 2005 Aug;44(8):800-4

pubmed: 16157976

Int J Clin Oncol. 2019 Jul;24(7):798-806

pubmed: 30783810

Dis Markers. 2014;2014:860419

pubmed: 25580051

BMC Cancer. 2020 Jun 26;20(1):594

pubmed: 32586289

J Thorac Oncol. 2015 Aug;10(8):1133-41

pubmed: 26039012

Lung Cancer. 2006 Jul;53(1):111-5

pubmed: 16697073

Thorac Cancer. 2020 Apr;11(4):888-897

pubmed: 32087605

Cancer Lett. 2014 Apr 10;345(2):164-73

pubmed: 23988267

Ann Thorac Surg. 2016 May;101(5):1909-14

pubmed: 26897321

J Cancer. 2019 May 12;10(9):2047-2056

pubmed: 31205565

Ann Thorac Surg. 2015 Mar;99(3):983-9

pubmed: 25596870

J Thromb Thrombolysis. 2019 Nov;48(4):638-647

pubmed: 31228037